



National Imaging Associates, Inc.	
Clinical guidelines HEAD AND NECK CANCER	Original Date: June 2013
Radiation Oncology	Last Revised Date: April 2019
Guideline Number: NIA_CG_131	Implementation Date: January 2020

INDICATIONS FOR RADIATION THERAPY:

2D, 3D, IMRT and Brachytherapy techniques may be used as appropriate, depending on the tumor location and stage of disease (NCCN, 2018). Brachytherapy, where appropriate, may be utilized as a boost for 2D, 3D or IMRT courses of radiation therapy.

- Pre-operative radiation therapy
 - 2D/3D/IMRT – up to 35 fractions
- Definitive radiation therapy with or without concurrent chemotherapy
 - 2D/3D/IMRT – up to 42 fractions
 - Hyperfractionation - 81.6 Gy, 1.2 Gy per fraction BID (up to 68 fractions)
- Post-operative radiation therapy (up to 40 fractions)
 - Presence of adverse factors
 - pT3 or pT4 primary tumors
 - N2-3
 - Perineural invasion
 - Vascular tumor embolism
 - Extracapsular spread
 - Positive surgical margin
- Palliative radiation therapy if symptomatic up to 20 fractions
- Re-irradiation may be indicated if no metastatic disease present up to 34 fractions

TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW:

Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy is not a standard treatment option for the treatment of head and neck cancer. SBRT may be indicated for reirradiation (NCCN, 2018).

Proton Beam Radiation Therapy

Proton beam is not a standard treatment option for head and neck cancer.

BACKGROUND:

According to the American Society of Clinical Oncology, about 3% of all cancers in the United States occur in the head and neck. The majority of these tumors are squamous cell carcinoma, with human papilloma virus infection, tobacco and alcohol use regarded as risk factors (ASCO, 2015). Due to the complexity of tumors arising from the head and neck region, it is not unusual for management to include an initial evaluation and development of a plan by a multidisciplinary team, including surgery,

radiotherapy, medical oncology, and dental. Although single modality treatment with either surgery or radiotherapy is not uncommon with patients with early stage disease, combined modality therapy is appropriate for the majority of patients with locally or regionally advanced stage of disease (NCCN, 2018). The primary sites for head and neck tumors include paranasal sinuses, the lip, oral cavity, salivary glands, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, nasopharynx, and occult head and neck primary sites.

This guideline outlines several methods suitable for delivering radiation therapy to the head and neck area. Various radiotherapy techniques may be used as appropriate, depending on the stage, location, and expertise of the radiation oncologist (NCCN, 2018). Multidisciplinary management is recommended to best achieve tumor control while reducing toxicity (ASCO, 2015). These are generally accepted practice guidelines, however, cannot incorporate all possible clinical variations, and thus are not intended to replace good clinical judgment or individualization of treatments.

IMRT, 3D, 2D, and brachytherapy techniques may be used as appropriate, depending on the tumor location, stage of disease, and experience/availability of dosimetry/medical physics support (NCCN, 2018). Intensely modulated radiation therapy (IMRT) has been shown to be useful in reducing long term side effects in oropharyngeal, paranasal sinus, and nasopharyngeal cancers by reducing dose to normal surrounding tissue, including the salivary gland and brain (including temporal lobes, auditory apparatus, and optic structures). The application of IMRT to other sites of the head and neck is evolving with the recommendation to use at the discretion of the treating physicians. IMRT can be delivered with various dose fractionation schemes, including simultaneous integrated boost, sequential boost, and concomitant accelerated boost. IMRT has been shown to be beneficial in treating certain head and neck cancers by reducing dose to the salivary glands, brain, auditory apparatus, and optic structures. Low dose or high dose brachytherapy may be appropriate in certain cases.

POLICY HISTORY:

Review Date: February 2019

Review Summary: Added and updated references

REFERENCES:

- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Adjuvant therapy for resected squamous cell carcinoma of the head and neck*. <https://acsearch.acr.org/docs/70542/Narrative/>. Published 2011a. Accessed March 26, 2015.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Aggressive nonmelanomatous skin cancer of the head and neck*. <https://acsearch.acr.org/docs/3091669/Narrative/>. Published 2014a. Accessed March 26, 2015.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Ipsilateral radiation for squamous cell carcinoma of the tonsil*. <https://acsearch.acr.org/docs/70730/Narrative/>. Published 2011b. Accessed March 26, 2015.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Local-regional therapy for resectable oropharyngeal squamous cell carcinomas*. <https://acsearch.acr.org/docs/69505/Narrative/>. Published 2015. Accessed May 11, 2016.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Retreatment of recurrent head and neck cancer after prior definitive radiation*. <https://acsearch.acr.org/docs/69506/Narrative/>. Published 2014b. Accessed March 26, 2015.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Thyroid carcinoma*. <https://acsearch.acr.org/docs/3082874/Narrative/>. Published 2013. Accessed March 26, 2015.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. *Treatment of stage I T1 glottic cancer*. <https://acsearch.acr.org/docs/71099/Narrative/>. Published 2012. Accessed March 26, 2015.
- Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome [abstract 5507]. *J Clin Oncol*. 2010; 28(Suppl 15). http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5507.
- American Society of Clinical Oncology (ASCO). *Head and Neck Cancer: Statistics*. <http://www.cancer.net/cancer-types/head-and-neck-cancer/statistics>. Published 2015. Accessed May 11, 2016.
- Buiret G, Combe C, Favrel V, et al. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys*. 2010; 77:430-437. doi: 10.1016/j.ijrobp.2009.04.066.
- Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. *Int J Radiat Oncol Biol Phys*. 2009; 73:1096-1103. doi: 10.1016/j.ijrobp.2008.05.024.
- Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). *Int J Radiat Oncol Biol Phys*. 2009; 73:9-14. doi: 10.1016/j.ijrobp.2008.04.049.

Hitt R, Grau JJ, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) [abstract 6009]. *J Clin Oncol*. 2009; 27(Suppl 15). <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6009>.

Holmes T, Das R, Low D, et al. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. *Int J Radiat Oncol Biol Phys*. 2009; 74:1311-1318. doi: 10.1016/j.ijrobp.2009.04.037.

IMRT Documentation Working Group, Holmes T, Das R, et al. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. *Int J Radiat Oncol Biol Phys*. 2009; 74(5):1311-1318. doi: 10.1016/j.ijrobp.2009.04.037.

Jemal A, Siegel R, Xu J, et al. Cancer statistics. *CA Cancer J Clin*. 2010; 60:277-300. doi: 10.3322/caac.20073.

Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPIN study [abstract 6010]. *J Clin Oncol*. 2009; 27(Suppl 15). <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6010>.

Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. *J Natl Cancer Inst*. 2009; 101:142-152. doi: 10.1093/jnci/djn460.

Madani I, Bonte K, Vakaet L, et al. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. *Int J Radiat Oncol Biol Phys*. 2009; 73:424-432. <https://biblio.ugent.be/publication/700587>.

National Comprehensive Cancer Network (NCCN). Head and Neck Cancers v1.2018. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed April 25, 2018.

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Head and neck cancers v2.2018. NCCN; Fort Washington, PA. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed February 10, 2019.

Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicenter randomized controlled trial. *Lancet Oncol*. 2011; 12(2):127-136. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(10\)70290-4/fulltext?_eventId=login](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70290-4/fulltext?_eventId=login). Accessed November 9, 2012.

Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. *Lancet Oncol*. February 2011; 12(2):127-136. doi: 10.1016/S1470-2045(10)70290-4.

Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head

and neck cancer: A phase II randomized study. *Ann Oncol*. 2010; 21:1515-1522. doi: 10.1093/annonc/mdp573.

Pfister D, Cassileth B, Deng G, et al. Acupuncture for pain and dysfunction after neck dissection: Results of a randomized controlled trial. *J Clin Oncol*. 2010; 28:2565-2570. doi: 10.1200/JCO.2009.26.9860.

Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst*. 2009; 101:498-506. doi: 10.1093/jnci/djp007.

Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. *Semin Radiat Oncol*. 2009; 19:29-34. doi: 10.1016/j.semradonc.2008.09.006.

Salama JK, Haddad RI, Kies MS, et al. Clinical practice recommendations for radiotherapy planning following induction chemotherapy in locoregionally advanced head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2009; 75(3):725-733. doi: 10.1016/j.ijrobp.2008.11.059.

Reviewed / Approved by  Patrick Browning, VP, Medical Director

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.